**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 68661

**Manuscript Type:** ORIGINAL ARTICLE

***Clinical Trials Study***

**Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer**

Yan MH *et al*. Induction chemotherapy for locally advanced esophageal cancer

Mao-Hui Yan, Fang Liu, Bao-Lin Qu, Bo-Ning Cai, Wei Yu, Xiang-Kun Dai

**Mao-Hui Yan, Fang Liu, Bao-Lin Qu, Bo-Ning Cai, Wei Yu, Xiang-Kun Dai,** Department of Radiotherapy, The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital, Beijing 100853, China

**Author contributions:** Yan MH, Liu F, Qu BL, Cai BL, Yu W, and Dai XK contributed equally to this work; Yan MH and Liu F designed the research study; Yan MH, Liu F, Qu BL, Cai BL, Yu W, and Dai XK performed the research; Yan MH, Cai BL, and Yu W contributed analytic tools; Yan MH, Liu F, Qu BL, Cai BL, Yu W, and Dai XK analyzed the data and wrote the manuscript; and all authors have read and approved the final manuscript.

**Corresponding author: Fang Liu, MD, Associate Chief Physician,** Department of Radiotherapy, the First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. liufangfsq@163.com

**Received:** June 15, 2021

**Revised:** July 18, 2021

**Accepted:** August 23, 2021

**Published online:** November 15, 2021

**Abstract**

BACKGROUND

Albumin-bound paclitaxel (ABP) has been used as second- and higher-line treatments for advanced esophageal cancer, and its efficacy and safety have been well demonstrated. Lobaplatin (LBP) is a third-generation platinum antitumor agent; compared with the first two generations of platinum agents, it has lower toxicity and has been approved for the treatment of breast cancer, small cell lung cancer, and chronic granulocytic leukemia. However, its role in the treatment of esophageal cancer warrants further investigations.

AIM

To investigate the efficacy and safety of induction chemotherapy with ABP plus LBP followed by concurrent radiochemotherapy (RCT) for locally advanced esophageal cancer.

METHODS

Patients with pathologically confirmed advanced esophageal squamous cell carcinoma (ESCC) at our hospital were enrolled in this study. All patients were treated with two cycles of induction chemotherapy with ABP plus LBP followed by concurrent RCT: ABP 250 mg/m2, ivgtt, 30 min, d1, every 3 wk; and LBP, 30 mg/m2, ivgtt, 2 h, d1, every 3 wk. A total of four cycles were scheduled. The dose of the concurrent radiotherapy was 56-60 Gy/28-30 fractions, 1.8-2.0 Gy/fraction, and 5 fractions/wk.

RESULTS

A total of 29 patients were included, and 26 of them completed the treatment protocol. After the induction chemotherapy, the objective response rate (ORR) was 61.54%, the disease control rate (DCR) was 88.46%, and the progressive disease (PD) rate was 11.54%; after the concurrent RCT, the ORR was 76.92%, the DCR was 88.46%, and the PD rate was 11.54%. The median progression-free survival was 11.1 mo and the median overall survival was 15.83 mo. Cox multivariate analysis revealed that two cycles of induction chemotherapy followed by concurrent RCT significantly reduced the risk of PD compared with two cycles of chemotherapy alone (*P* = 0.0024). Non-hematologic toxicities were tolerable, and the only grade 3 non-hematologic toxicity was radiation-induced esophagitis (13.79%). The main hematologic toxicity was neutropenia, and no grade 4 adverse event occurred.

CONCLUSION

Induction chemotherapy with ABP plus LBP followed by concurrent RCT is effective in patients with locally advanced ESCC, with mild adverse effects. Thus, this protocol is worthy of clinical promotion and application.

**Key Words:** Esophageal squamous cell carcinoma; Esophagus cancer; Induction chemotherapy; Concurrent radiochemotherapy; Radiotherapy; Chemotherapy; Albumin-bound paclitaxel; Lobaplatin

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK. Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer. *World J Gastrointest Oncol* 2021; 13(11): 1781-1790

**URL:** https://www.wjgnet.com/1948-5204/full/v13/i11/1781.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v13.i11.1781

**Core Tip:** This study aimed to investigate the efficacy and safety of induction chemotherapy with albumin-bound paclitaxel (ABP) plus lobaplatin followed by concurrent radiochemotherapy (RCT) for locally advanced esophageal cancer. A total of 29 patients were included, and 26 of them completed the treatment protocol. Induction chemotherapy with ABP plus lobaplatin followed by concurrent RCT is effective in patients with locally advanced esophageal squamous cell carcinoma, with mild adverse effects. Thus, this protocol is worthy of clinical promotion and application.

**INTRODUCTION**

Esophageal cancer is one of the most common forms of cancer worldwide, with an estimated 572000 new cases and 509000 deaths in 2018[1,2]. The most common type of esophageal cancer in China is esophageal squamous cell carcinoma (ESCC), which accounts for 89% of all esophageal cancer cases[3]. The 5-year survival rate of Chinese ESCC patients is 20%-30% overall[4]. The preferred treatment modality for esophageal cancer is surgery, but 80% of patients are no longer eligible for radical surgery upon diagnosis[5,6]. Concurrent chemoradiotherapy has been found to yield better overall survival than radiotherapy[7–9]. While definitive radiochemotherapy (RCT) remains the mainstay of treatment for locally advanced esophageal cancer[10], the treatment modalities have long been controversial. Several clinical trials have explored and evaluated the multidisciplinary treatments for advanced unresectable esophageal cancer, but there is still no standardized treatment protocol. In the COSMOS trial[11], the 1-year survival rate of patients with esophageal cancer treated by surgery after induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF) regimen was 67.9%, which confirmed the efficacy of induction chemotherapy followed by definitive RCT in treating esophageal cancer. Another multicenter randomized controlled trial (JCOG1510)[12] further confirmed that induction chemotherapy + surgery or induction chemotherapy + concurrent definitive RCT was superior to concurrent definitive RCT in terms of overall survival (OS) in patients with locally advanced unresectable ESCC. Paclitaxel combined with carboplatin is one of the standard chemotherapy regimens recommended in guidelines, but there is limited evidence for other taxanes and platinum agents. Nanoparticle albumin-bound (nab)-paclitaxel has been shown to provide significant efficacy and safety benefits over paclitaxel and is currently approved for the treatment of breast cancer, lung cancer, pancreatic cancer, and melanoma. In recent years, albumin-bound paclitaxel (ABP) has been used as second- and higher-line treatments for advanced esophageal cancer, and its efficacy and safety have been well demonstrated. Lobaplatin (LBP) is a third-generation platinum antitumor agent; compared with the first two generations of platinum agents, it has lower toxicity and has been approved for the treatment of breast cancer, small cell lung cancer, and chronic granulocytic leukemia. However, its role in the treatment of esophageal cancer warrants further investigations.

Thus, we conducted the present prospective study to investigate the efficacy and safety of induction chemotherapy with ABP plus LBP followed by concurrent RCT in the treatment of locally advanced esophageal cancer.

**MATERIALS AND METHODS**

***Subjects***

ESCC patients attending our hospital were included according to the following inclusion criteria: (1) Patients voluntarily participated in this study, had good compliance, could cooperate with the trial requirements during the observation and follow-up periods, and signed an informed consent form; (2) Patients with histopathologically confirmed stage III or IVA unresectable advanced ESCC, which had not been treated with anti-tumor drugs other than the study drug within the past 4 wk; and the patient could receive the specialized anti-tumor treatment; (3) Patients with at least one measurable lesion [≥ 1 cm on computed tomography (CT) or ≥ 2 cm on other imaging modes]; (4) Patients with an Eastern Cooperative Oncology Group score of ≤ 2 and having indications for chemotherapy; (5) PPatients who lost ≤ 10% of the body weight in the last 6 mo and could tolerate radiotherapy; (6) Males or females aged 18-76 years; (7) Patients with the following laboratory-confirmed bone marrow, liver, kidney, and heart functions within 7 d before the first dose: White blood cell count ≥ 3000/µL, absolute neutrophil count ≥ 1500/µL, platelet count ≥ 100000/µL, and hemoglobin ≥ 9.0 g/dL; aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times upper limit of normal (ULN), and alkaline phosphatase ≤ 4 times ULN, and total bilirubin ≤ 1.5 times ULN; serum creatinine ≤ 1.5 times ULN and blood urea nitrogen ≤ 2.5 times ULN; prothrombin time and/or international normalized ratio or partial thromboplastin time ≤ 1.5 times ULN; and left ventricular ejection fraction ≥ 60% as assessed by Doppler ultrasound, and electrocardiographic findings were basically normal; and (8) Females must use contraception during the treatment and within 6 mo upon the completion of the treatment, and they should not be pregnant or lactating; and males must take birth control measures during the treatment and within 6 mo upon the completion of the treatment.

The exclusion criteria were: (1) Patients with severe acute infection, purulent/ chronic infection, or protracted wound healing; (2) Patients with esophageal perforation (*e.g.*, with existing or possible tracheoesophageal fistula), which had shown obvious symptoms and multiple distant metastases; (3) Patients who had abnormal coagulation and/or bleeding tendency (*e.g.*, active peptic ulcers) or were receiving a thrombolytic or anticoagulant therapy; (4) Patients with pre-existing severe cardiac disease, including: Congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina pectoris, myocardial infarction within 6 mo, severe heart valve disease, and resistant hypertension; (5) Patients with uncontrollable neurological or psychiatric diseases or mental disorders; the patients had poor compliance and were unable to follow the treatment protocol or describe their treatment responses; and (6) Patients with severe cirrhosis and/or severe renal insufficiency.

***Treatments***

All patients were treated with two cycles of induction chemotherapy with ABP (Keaili, produced by CSPC Ouyi Pharmaceutical Co., Ltd) combined with LBP: ABP 250 mg/m2, ivgtt, 30 min, d1, every 3 wk; and LBP, 30 mg/m2, ivgtt, 2 h, d1, every 3 wk. Concurrent RCT was given after the induction chemotherapy. Intensity-modulated radiation therapy (56-60 Gy/28-30 fractions, 1.8-2.0 Gy/fraction, 5 fractions/wk) was applied as the radiotherapy. Two cycles of chemotherapy was applied on days 1 and 21 of radiotherapy, and the chemotherapy regimen was the same as that in the induction chemotherapy.

***Evaluation of efficacy and adverse events***

Chest CT, magnetic resonance imaging, and positron emission tomography-CT (if necessary) were performed after induction chemotherapy, 1 mo after concurrent RCT, and at each follow-up visit. The efficacy was evaluated using the benchmarks of Response Evaluation Criteria in Solid Tumors version 1.1, which included complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD); the objective remission rate (ORR) was calculated using the following formula: ORR = (CR + PR)/total cases × 100%.

The adverse events were graded according to the US NCI Common Terminology Criteria for Adverse Events version 3.0. Adverse events occurring during the study period were recorded continuously.

After the completion of treatment, all patients were followed by telephone or outpatient visits.

***Primary and secondary outcome measures***

The primary outcome measure was progression-free survival (PFS). The secondary outcome measures included OS, ORR after induction chemotherapy, ORR after concurrent RCT, correlations with prognostic factors, and adverse events.

***Statistical analysis***

Examination indicators at baseline were described. Count data are presented with the number and percentage of cases; for measurement data, the mean, standard deviation, median, and maximum and minimum values were calculated. For the efficacy indicators, ORR is presented using the number and percentage of cases and PFS and OS are described using Kaplan-Meier curves; the median and 95% confidence interval (CI) were calculated, and factors affecting disease progression were explored using COX multivariate regression, in which hazard ratio (HR) and 95%CI are listed. The types and severity of adverse events during the trial were described, and the incidence of adverse events was calculated (presented as number and percentage of cases). All statistical analyses were performed using SPSS 19.0 software package.

**RESULTS**

***Treatment completion***

A total of 29 patients with locally advanced ESCC were included in this study between April 2019 and October 2020, and the baseline data of these patients are shown in Table 1. Three patients withdrew from the study because of surgery (*n* = 1), PD after enrollment without treatment (*n* = 1), and loss to follow-up (*n* = 1). All patients (100%) completed the induction chemotherapy. The completion rate of the entire study protocol (2 cycles of induction chemotherapy + 2 cycles of concurrent RCT) was 65.38% (*n* = 17). Five patients (19.23%) underwent two cycles of induction chemotherapy + one cycle of concurrent RCT, and the reasons for not completing the entire protocol were grade III radiation-induced esophagitis in three cases and grade III myelosuppression in two. Four (13.79%) patients underwent two cycles of induction chemotherapy only, among whom three experienced disease progression and one refused to receive concurrent radiotherapy.

***Short-term efficacy***

After two cycles of induction chemotherapy, ORR was 61.54% (*n* = 16); the disease control rate (DCR) was 88.46% (*n* = 23), among which PR was achieved in 16 (61.54%) cases and SD in 7 (26.92%); PD was noted in three (11.54%) cases, including *in situ* progression (*n* = 1), mediastinal lymph node progression (*n* = 1), and esophagotracheal fistula (*n* = 1). Among patients who completed induction chemotherapy + concurrent RCT, the evaluated ORR was 76.92% (*n* = 20) and the DCR was 88.46% (*n* = 23), among which PR was achieved in 20 (76.92%) cases and SD in 3 (11.54%); PD was noted in three (11.54%) cases (Table 2).

***Follow-up and long-term outcomes***

By October 2020, 29 patients had been followed for a median of 15.28 (5-28) mo. Disease progression occurred in 14 (48.28%) patients, including four (17.24%) cases of *in situ* progression, two (6.90%) cases of lymph node metastasis, and seven (24.14%) cases of distant metastasis [including two (6.90%) cases of liver metastasis, one (3.45%) case of brain metastasis, three (10.34%) cases of lung metastasis, and one (3.45%) case of spleen and kidney metastases]. Thirteen patients died. The median PFS was 11.1 mo, the median OS was 15.83 mo, and the 1-year OS was 42% (Figure 1).

***Adverse events and safety***

The incidence of post-treatment hematologic toxicities is as follows. After the treatment, the incidence of grade 3 anemia, leukopenia, neutropenia, and thrombocytopenia was 0%, 10.35%, 6.9%, and 0%, respectively. The incidence of non-hematologic toxicities including decreased appetite, fatigue, radiation-induced esophagitis, decreased body weight, and abnormal liver function was 13.79%, 13.79%, 34.48%, 3.45%, and 3.45%, respectively. These non-hematologic toxicities were generally grade 1 or 2; the only grade 3 non-hematologic toxicity was radiation-induced esophagitis, and no grade 4 toxicity was noted (Table 3).

***Results of multivariate Cox analysis***

The number of chemotherapy cycles was a statistically significant factor affecting the prognosis (*P* = 0.0024). Patients with esophageal cancer who received three (HR = 0.0555; 95%CI: 0.0066-0.4668) or four cycles of chemotherapy (HR = 0.0043; 95%CI: 0.0002-0.0992) had a significantly lower risk of disease progression compared to those who received only two cycles of induction chemotherapy.

The prognostic impact of the overall nutritional score was not statistically significant (*P* = 0.0826); however, compared to patients with an initial score of 5, patients with an initial score of 1 (HR = 0.0037; 95%CI: 0.0001-0.2715), 3 (HR = 0.0077; 95%CI: 0.0001-0.6176), and 4 (HR = 0.0131; 95%CI: 0.0002-0.7049) had better prognoses (Figure 2).

**DISCUSSION**

The efficacy of induction chemotherapy followed by definitive RCT in treating esophageal cancer has been proved in recent years. In the COSMOS trial[11], the 1-year survival rate of patients with esophageal cancer treated by surgery after induction chemotherapy with DCF regimen reached 67.9%. Another multicenter randomized controlled trial (JCOG1510)[12] further confirmed that induction chemotherapy + surgery or induction chemotherapy + concurrent definitive RCT was superior to concurrent definitive RCT in terms of OS in patients with locally advanced unresectable ESCC. In the current study, the ORR after two cycles of induction chemotherapy with ABP combined with LBP was 61.54%, with a DCR of 88.46%; 100% of our subjects completed the induction therapy without severe hematologic toxicities or chemotherapy-induced nausea and vomiting. Twenty-two patients further received concurrent RCT; 65.38% of them completed induction chemotherapy plus concurrent RCT, while 19.23% received one cycle of concurrent RCT due to radiation-induced esophagitis or myelosuppression. The ORR was 76.92% and disease control rate was 88.46% after the completion of induction chemotherapy followed by concurrent RCT, which were comparable to those of previous studies; the median PFS was 11.1 mo and the median OS was 15.83 mo; notably, the 1-year PFS rate was 49.45% and the 1-year OS rate was 64.96%. Cox multivariate analysis of the efficacy and prognosis concluded that two cycles of induction chemotherapy followed by concurrent RCT significantly reduced the risk of disease progression compared with two cycles of chemotherapy only (*P* = 0.0024), suggesting that induction chemotherapy combined with definitive RCT is an efficacious and well-tolerated treatment modality in patients with esophageal cancer. With fewer and milder toxicities, it enhances chemotherapy tolerability and prolongs survival.

Wang *et al*[13] demonstrated that weekly nab-paclitaxel plus cisplatin with concurrent definitive radiotherapy is an effective and well-tolerated treatment option for ESCC. In addition, Wang *et al*[14] compared the values of nanoparticle albumin-bound paclitaxel plus cisplatin (nab-TP) *vs* solvent-based paclitaxel plus cisplatin (sb-TP) and found that nab-TP demonstrated a higher ORR (50% *vs* 30%, *P* = 0.082) and disease control rate (81% *vs* 65%, *P* = 0.124) than sb-TP, as well as a longer median PFS (6.1 mo, 95%CI: 5.3-6.9) (*P* = 0.029). In contrast, LBP used in our current study is a new-generation platinum drug. Many studies have shown that LBP has therapeutic efficacy in the treatment of advanced esophageal cancer, with tolerable side effects[15-17]. Among patients who received induction therapy plus concurrent RCT, the incidence of grade 3 leukopenia and neutropenia was 10.35% and 6.9%, respectively. The non-hematologic toxicities including decreased appetite, fatigue, weight loss, and abnormal liver function were generally grade 1 or 2; the only grade 3 non-hematologic toxicity was radiation-induced esophagitis, and no grade 4 toxicity was noted. Thus, ABP combined with LBP has acceptable adverse effects and can achieve good long-term survival in patients with locally advanced ESCC when used either as an induction chemotherapy regimen or as a concurrent chemotherapy regimen.

However, although RCT is the main treatment modality for patients with stage II-III esophageal cancer who refuse surgery or has a contraindication for surgery and in patients with locally advanced unresectable (stage IVa) esophageal cancer[18,19], different patterns of recurrence and metastasis still occur. Sudo *et al*[20] reported the types of recurrence after definitive chemoradiotherapy: The incidence of luminal relapse, regional relapse, distant metastasis, new cancer diagnosed by esophagogastroduodenoscopy (NC-E), and new cancer other than NC-E (NC-O) was 14%, 6%, 19%, 17%, and 8%, respectively. In the present study, disease progression occurred in 14 (48.28%) patients, including five (17.24%) cases of *in situ* progression, two (6.90%) cases of lymph node metastasis, and eight (27.59%) cases of distant metastasis [including two (6.90%) cases of liver metastasis, one (3.45%) case of brain metastasis, three (10.34%) cases of lung metastasis, and one (3.45%) case of spleen and kidney metastases]. The results of this study also suggested that nutritional scores before and during treatment had an impact on prognosis, which needs to be further verified in studies with larger sample sizes.

**CONCLUSION**

In conclusion, induction chemotherapy with ABP plus LBP followed by concurrent RCT is effective in patients with locally advanced ESCC, with mild adverse effects. Thus, this protocol is worthy of clinical promotion and application. However, as an interim report, this study was limited by its short follow-up intervals, and patients’ survival and tumor recurrence/metastasis need to be further investigated. In addition, the induction chemotherapy regimen as well as the optimal dose and fractionation schedule of the definitive RCT for ESCC deserves further clinical research.

**ARTICLE HIGHLIGHTS**

***Research background***

The most common type of esophageal cancer in China is esophageal squamous cell carcinoma (ESCC), which accounts for 89% of all esophageal cancer cases. The 5-year survival rate of Chinese ESCC patients is 20%-30% overall. The preferred treatment modality for esophageal cancer is surgery, but 80% of patients are no longer eligible for radical surgery upon diagnosis.

***Research motivation***

We conducted the present prospective study to investigate the efficacy and safety of induction chemotherapy with albumin-bound paclitaxel (ABP) plus lobaplatin (LBP) followed by concurrent radiochemotherapy (RCT) in the treatment of locally advanced esophageal cancer.

***Research objectives***

This study aimed to investigate the efficacy and safety of induction chemotherapy with ABP plus LBP followed by concurrent RCT for locally advanced esophageal cancer.

***Research methods***

Patients with pathologically confirmed advanced ESCC were enrolled in this study. All patients were treated with two cycles of induction chemotherapy with ABP plus LBP followed by concurrent RCT. A total of four cycles were scheduled.

***Research results***

Cox multivariate analysis revealed that two cycles of induction chemotherapy followed by concurrent RCT significantly reduced the risk of progressive disease compared with two cycles of chemotherapy alone. Non-hematologic toxicities were tolerable, and the only grade 3 non-hematologic toxicity was radiation-induced esophagitis. The main hematologic toxicity was neutropenia, and no grade 4 adverse event occurred.

***Research conclusions***

Induction chemotherapy with ABP plus LBP followed by concurrent RCT is effective in patients with locally advanced ESCC, with mild adverse effects. Thus, this protocol is worthy of clinical promotion and application.

***Research perspectives***

As an interim report, this study was limited by its short follow-up intervals, and patients’ survival and tumor recurrence/metastasis need to be further investigated.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; **68**: 7-30 [PMID: 29313949 DOI: 10.3322/caac.21442]

3 **Zeng H**, Zheng R, Zhang S, Zuo T, Xia C, Zou X, Chen W. Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries. *Thorac Cancer* 2016; **7**: 232-237 [PMID: 27042227 DOI: 10.1111/1759-7714.12322]

4 **Allemani C**, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo E Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet* 2018; **391**: 1023-1075 [PMID: 29395269 DOI: 10.1016/S0140-6736(17)33326-3]

5 **Tu CC**, Hsu PK. The frontline of esophageal cancer treatment: questions to be asked and answered. *Ann Transl Med* 2018; **6**: 83 [PMID: 29666806 DOI: 10.21037/atm.2017.10.31]

6 **Mariette C**, Markar SR, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, D'Journo XB, Brigand C, Perniceni T, Carrère N, Mabrut JY, Msika S, Peschaud F, Prudhomme M, Bonnetain F, Piessen G; Fédération de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Group. Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer. *N Engl J Med* 2019; **380**: 152-162 [PMID: 30625052 DOI: 10.1056/NEJMoa1805101]

7 **Gao XS**, Qiao X, Wu F, Cao L, Meng X, Dong Z, Wang X, Gao G, Wu TT, Komaki R, Chang JY. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. *Int J Radiat Oncol Biol Phys* 2007; **67**: 389-396 [PMID: 17236963 DOI: 10.1016/j.ijrobp.2006.09.015]

8 **Cooper JS**, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. *JAMA* 1999; **281**: 1623-1627 [PMID: 10235156 DOI: 10.1001/jama.281.17.1623]

9 **Chun SG**, Skinner HD, Minsky BD. Radiation Therapy for Locally Advanced Esophageal Cancer. *Surg Oncol Clin N Am* 2017; **26**: 257-276 [PMID: 28279468 DOI: 10.1016/j.soc.2016.10.006]

10 **Park R**, Williamson S, Kasi A, Saeed A. Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer. *Anticancer Res* 2018; **38**: 5569-5580 [PMID: 30275174 DOI: 10.21873/anticanres.12891]

11 **Yokota T**, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, Hironaka S, Kii T, Kojima Y, Akutsu Y, Matsushita H, Kawakami K, Mori K, Nagai Y, Asami C, Kitagawa Y. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. *Br J Cancer* 2016; **115**: 1328-1334 [PMID: 27811857 DOI: 10.1038/bjc.2016.350]

12 **Terada M**, Hara H, Daiko H, Mizusawa J, Kadota T, Hori K, Ogawa H, Ogata T, Sakanaka K, Sakamoto T, Kato K, Kitagawa Y. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). *Jpn J Clin Oncol* 2019; **49**: 1055-1060 [PMID: 31411696 DOI: 10.1093/jjco/hyz112]

13 **Wang D**, Zhang W, Qian D, Guan Y, Chen X, Zhang H, Wang J, Pang Q. Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial. *Onco Targets Ther* 2018; **11**: 6333-6338 [PMID: 30319273 DOI: 10.2147/OTT.S168275]

14 **Wang HY**, Yao ZH, Tang H, Zhao Y, Zhang XS, Yao SN, Yang SJ, Liu YY. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma. *Onco Targets Ther* 2016; **9**: 5663-5669 [PMID: 27713635 DOI: 10.2147/OTT.S108580]

15 **Jia XJ**, Huang JZ. Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer. *Asian Pac J Cancer Prev* 2015; **16**: 6595-6597 [PMID: 26434880 DOI: 10.7314/apjcp.2015.16.15.6595]

16 **Chen MQ**, Chen C, Lu HJ, Xu BH. The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma. *J Thorac Dis* 2015; **7**: 1749-1755 [PMID: 26623097 DOI: 10.3978/j.issn.2072-1439.2015.10.23]

17 **Chen J**, Su T, Lin Y, Wang B, Li J, Pan J, Chen C. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma. *Clin Transl Oncol* 2018; **20**: 411-419 [PMID: 28779422 DOI: 10.1007/s12094-017-1734-y]

18 **Kitagawa Y**, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. *Esophagus* 2019; **16**: 1-24 [PMID: 30171413 DOI: 10.1007/s10388-018-0641-9]

19 **Ishida K**, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). *Jpn J Clin Oncol* 2004; **34**: 615-619 [PMID: 15591460 DOI: 10.1093/jjco/hyh107]

20 **Sudo K**, Kato K, Kuwabara H, Sasaki Y, Takahashi N, Shoji H, Iwasa S, Honma Y, Okita NT, Takashima A, Hamaguchi T, Yamada Y, Ito Y, Itami J, Fukuda T, Tobinai K, Boku N. Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma. *Oncology* 2018; **94**: 47-54 [PMID: 29080886 DOI: 10.1159/000480515]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital Institutional Review Board (Approval No. S2016-099-02).

**Clinical trial registration statement:** This study is registered at Chinese Clinical Trial Registry. The registration identification number is ChiCTR1900025080.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** None.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author at email address. Participants gave informed consent for data sharing.

**CONSORT 2010 statement:** The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review started:** June 15, 2021

**First decision:** July 16, 2021

**Article in press:** August 23, 2021

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B, B


Grade C (Good): 0


Grade D (Fair): 0

Grade E (Poor): 0


**P-Reviewer:** Brown SR, Gurland B, Werdana VAP **S-Editor:** Wang JL **L-Editor:** Wang TQ **P-Editor:** Li X

**Figure Legends**





**Figure 1 Cumulative progression-free survival and overall survival.** A: 1-year progression-free survival; B: 1-year overall survival. PFS: Progression-free survival; OS: Overall survival.

****

**Figure 2 Multivariate Cox analysis.**

**Table 1 Baseline characteristics of patients**

|  |  |
| --- | --- |
| **Feature** | ***n* (%)** |
| Gender |  |
| Male | 29 (100) |
| Female | 0 (0) |
| Age [yr; median (range)] | 62 (56, 65) |
| Clinical stage |  |
| III | 15 (51.7) |
| IV | 14 (48.3) |
| Tumor location |  |
| Upper thoracic esophagus | 6 (20.7) |
| Upper part of middle thoracic esophagus | 3 (10.3) |
| Middle thoracic esophagus | 6 (20.7) |
| Lower part of middle thoracic esophagus | 8 (27.6) |
| Lower thoracic esophagus | 6 (20.7) |

**Table 2 Short-term efficacy, *n* (%)**

|  |  |  |
| --- | --- | --- |
|  | **After induction chemotherapy** | **After induction chemotherapy + concurrent radiochemotherapy** |
| ORR | 16 (61.54) | 20 (76.92) |
| PR | 16 (61.54) | 20 (76.92) |
| SD | 7 (26.92) | 3 (11.54) |
| PD | 3 (11.54) | 3 (11.54) |

ORR: Objective response rate; PR: Partial response; SD: Stable disease; PD: Progressive disease.

**Table 3 Adverse events (*n* = 29)**

|  |  |  |
| --- | --- | --- |
|  | **Grade 1 or 2 (%)** | **Grade 3 (%)** |
| Hematologic toxicities |  |  |
| Anemia | 3.85 | 0 |
| Leukopenia | 69.23 | 10.35 |
| Neutropenia | 61.54 | 6.9 |
| Thrombocytopenia | 15.4 | 0 |
| Non-hematologic toxicities |  |  |
| Decreased appetite | 13.79 | 0 |
| Fatigue | 13.79 | 0 |
| Radiation-induced esophagitis | 34.48 | 13.79 |
| Decreased body weight | 3.45 | 0 |
| Abnormal liver function | 3.45 | 0 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**